A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

This study is testing a new oral pill called KT-621 in adults with moderate to severe eosinophilic asthma — a type of asthma driven by an overactive immune response involving high levels of a white blood cell called eosinophils. Despite being on maximum inhaler therapy, these patients still experience frequent asthma attacks. **You may be eligible if...** - You are 18–75 years old - You have had a doctor's diagnosis of asthma for at least 1 year - You are already on medium to high dose inhaled corticosteroids plus a long-acting bronchodilator (LABA) for at least 12 weeks - Your eosinophil count in blood tests is elevated - Your lung function test shows airflow limitation, but still responds to a rescue inhaler - You had at least one asthma attack in the past year requiring steroids or a hospital visit - Your asthma control questionnaire score indicates poor control **You may NOT be eligible if...** - You have a serious infection, immune condition, or other uncontrolled medical problem - You are pregnant, planning to become pregnant, or not using contraception Talk to your doctor to see if this trial is right for you.